Published Online
on September 24, 2007

A more recent version of this article appeared on November 1, 2007

This Article Full Text (PDF) All Versions of this Article: 50/5/851    most recent HYPERTENSIONAHA.107.099747v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schillaci, G. Articles by Mannarino, E. Search for Related Content PubMed PubMed Citation Articles by Schillaci, G. Articles by Mannarino, E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Diabetes High Blood Pressure Hazardous Substances DB LOSARTAN POTASSIUM Related Collections Primary prevention Hypertrophy Electrocardiology Type 2 diabetes Clinical Studies Related Article

Left Ventricular Hypertrophy Reversal and Prevention of Diabetes. Two Birds With One Stone?

Giuseppe Schillaci^*; Matteo Pirro; and Elmo Mannarino

From the Unit of Internal Medicine, Angiology and Arteriosclerosis Disease, University of Perugia, Perugia, Italy.

^* To whom correspondence should be addressed. E-mail: skill{at}unipg.it.

Related Article:

In-Treatment Resolution or Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Decreased Incidence of New-Onset Diabetes Mellitus in Hypertensive Patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study

Peter M. Okin, Richard B. Devereux, Katherine E. Harris, Sverker Jern, Sverre E. Kjeldsen, Lars H. Lindholm, Björn Dahlöf for the LIFE Study Investigators
Hypertension 2007 50: 984-990. [Abstract] [Full Text] [PDF]